741 related articles for article (PubMed ID: 19212958)
41. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
[TBL] [Abstract][Full Text] [Related]
42. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis.
Zhao J; Qiu W; Simeone DM; Lubman DM
J Proteome Res; 2007 Mar; 6(3):1126-38. PubMed ID: 17249709
[TBL] [Abstract][Full Text] [Related]
43. Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain.
Raju TS; Scallon B
Biotechnol Prog; 2007; 23(4):964-71. PubMed ID: 17571902
[TBL] [Abstract][Full Text] [Related]
44. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
Scallon BJ; Tam SH; McCarthy SG; Cai AN; Raju TS
Mol Immunol; 2007 Mar; 44(7):1524-34. PubMed ID: 17045339
[TBL] [Abstract][Full Text] [Related]
45. Glycosylation profiling of a therapeutic recombinant monoclonal antibody with two N-linked glycosylation sites using liquid chromatography coupled to a hybrid quadrupole time-of-flight mass spectrometer.
Lim A; Reed-Bogan A; Harmon BJ
Anal Biochem; 2008 Apr; 375(2):163-72. PubMed ID: 18249181
[TBL] [Abstract][Full Text] [Related]
46. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies.
Wagner-Rousset E; Bednarczyk A; Bussat MC; Colas O; Corvaïa N; Schaeffer C; Van Dorsselaer A; Beck A
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Sep; 872(1-2):23-37. PubMed ID: 18672411
[TBL] [Abstract][Full Text] [Related]
47. Characterization of nonenzymatic glycation on a monoclonal antibody.
Brady LJ; Martinez T; Balland A
Anal Chem; 2007 Dec; 79(24):9403-13. PubMed ID: 17985928
[TBL] [Abstract][Full Text] [Related]
48. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies.
Nechansky A; Schuster M; Jost W; Siegl P; Wiederkum S; Gorr G; Kircheis R
Mol Immunol; 2007 Mar; 44(7):1815-7. PubMed ID: 17011625
[TBL] [Abstract][Full Text] [Related]
49. A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis.
Mahan AE; Tedesco J; Dionne K; Baruah K; Cheng HD; De Jager PL; Barouch DH; Suscovich T; Ackerman M; Crispin M; Alter G
J Immunol Methods; 2015 Feb; 417():34-44. PubMed ID: 25523925
[TBL] [Abstract][Full Text] [Related]
50. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation.
Ha S; Ou Y; Vlasak J; Li Y; Wang S; Vo K; Du Y; Mach A; Fang Y; Zhang N
Glycobiology; 2011 Aug; 21(8):1087-96. PubMed ID: 21470983
[TBL] [Abstract][Full Text] [Related]
51. A platform for high-throughput molecular characterization of recombinant monoclonal antibodies.
Bailey MJ; Hooker AD; Adams CS; Zhang S; James DC
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Nov; 826(1-2):177-87. PubMed ID: 16174568
[TBL] [Abstract][Full Text] [Related]
52. Maximizing coverage of glycosylation heterogeneity in MALDI-MS analysis of glycoproteins with up to 27 glycosylation sites.
Zhang Y; Go EP; Desaire H
Anal Chem; 2008 May; 80(9):3144-58. PubMed ID: 18370425
[TBL] [Abstract][Full Text] [Related]
53. Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function.
Antes B; Amon S; Rizzi A; Wiederkum S; Kainer M; Szolar O; Fido M; Kircheis R; Nechansky A
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):250-6. PubMed ID: 17296336
[TBL] [Abstract][Full Text] [Related]
54. Assigning glycosylation sites and microheterogeneities in glycoproteins by liquid chromatography/tandem mass spectrometry.
Mechref Y; Madera M; Novotny MV
Methods Mol Biol; 2009; 492():161-80. PubMed ID: 19241032
[TBL] [Abstract][Full Text] [Related]
55. Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins.
Ruhaak LR; Huhn C; Waterreus WJ; de Boer AR; Neusüss C; Hokke CH; Deelder AM; Wuhrer M
Anal Chem; 2008 Aug; 80(15):6119-26. PubMed ID: 18593198
[TBL] [Abstract][Full Text] [Related]
56. Microheterogeneous monoclonal antibody subspecies with differential hepatitis C virus core antigen binding properties identified by SEC-HPLC.
Muerhoff AS; Rupprecht K; Ruan Q; Zeck B; Ramsay C; Zhao C; Desai SM
J Immunol Methods; 2009 Jun; 345(1-2):60-9. PubMed ID: 19375428
[TBL] [Abstract][Full Text] [Related]
57. Impact on N-glycosylation profile of monoclonal anti-D antibodies as a way to control their immunoregulatory and cytotoxic properties.
Olovnikova NI; Ershler MA; Grigorieva OV; Petrov AV; Miterev GY
Biochemistry (Mosc); 2012 Aug; 77(8):925-33. PubMed ID: 22860915
[TBL] [Abstract][Full Text] [Related]
58. Sculpting therapeutic monoclonal antibody N-glycans using endoglycosidases.
Trastoy B; Du JJ; García-Alija M; Li C; Klontz EH; Wang LX; Sundberg EJ; Guerin ME
Curr Opin Struct Biol; 2022 Feb; 72():248-259. PubMed ID: 34998123
[TBL] [Abstract][Full Text] [Related]
59. Impact of Fc N-glycan sialylation on IgG structure.
Zhang Z; Shah B; Richardson J
MAbs; 2019; 11(8):1381-1390. PubMed ID: 31411531
[TBL] [Abstract][Full Text] [Related]
60. IgG N-glycans.
Liu S; Liu X
Adv Clin Chem; 2021; 105():1-47. PubMed ID: 34809825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
